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Metabolic stability and its role in the discovery 
of new chemical entities
Determination of metabolic profiles of new chemical 
entities is a key step in the process of drug discovery, since 
it influences pharmacokinetic characteristics of therapeutic 
compounds. One of the main challenges of medicinal 
chemistry is not only to design compounds demonstrating 
beneficial activity, but also molecules exhibiting favourable 
pharmacokinetic parameters. Chemical compounds can be 
divided into those which are metabolized relatively fast 
and those which undergo slow biotransformation. Rapid 
biotransformation reduces exposure to the maternal 
compound and may lead to the generation of active, non-
active or toxic metabolites. In contrast, high metabolic 
stability may promote interactions between drugs and lead 
to parent compound toxicity. In the present paper, issues of 
compound metabolic stability will be discussed, with 
special emphasis on its significance, in vitro metabolic 
stability testing, dilemmas regarding in vitro-in vivo 
extrapolation of the results and some aspects relating to 
different preclinical species used in in vitro metabolic 
stability assessment of compounds.
Keywords: metabolic stability, biotransformation, intrinsic 
clearance, in vitro half-life, metabolites, new chemical entity
INTRODUCTION
To induce systemic effects in the body, xenobiotics such as drugs must pass plasma 
membranes in order to bind to the appropriate receptors. Subsequently, active lipophilic 
compounds are transformed to more polar derivatives, which can be easily eliminated 
from the body.
In general, drug metabolism can be divided into phase I and phase II. Phase I enzymes 
are cytochrome P450 (CYP) monooxygenases and flavin containing monooxygenases (FMO), 
which catalyze oxidation, reduction and hydrolysis reactions. In phase II biotransformation, 
metabolites rendered in phase I undergo conjugation reactions mediated by enzymes such 
as UDP-glucuronyl transferases or sulfotransferases (1–5). Determination of metabolic 
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stability and fate of a new chemical entity (NCE) is a crucial step in the early phases of the 
drug discovery and development process, since it greatly influences pharmacokinetic 
characteristics of therapeutic compounds (6–8). Key issues in this field are drug metabolic 
stability and drug metabolic profile evaluation.  
In general, therapeutic compounds can be divided into those which are metabolized 
relatively fast and those which undergo slow biotransformation. Rapid biotransformation 
usually reduces exposure to the bioactive maternal compound and may lead to the 
generation of active, non-active or toxic metabolites. However, too metabolically stable 
compounds may promote interactions between drugs and favour parent compound toxic 
effects.
Nowadays, one of the main challenges of medicinal chemistry and scientists is not 
only to design chemical compounds demonstrating beneficial activity, but also to select 
molecules exhibiting suitable pharmacokinetic parameters necessary to elicit a favourable 
duration of action (9). Therefore, metabolic stability issues of compounds will be discussed 
in this paper, with special emphasis on the significance of metabolic stability, overview of 
in vitro metabolic stability testing, dilemmas regarding in vitro-in vivo extrapolation 
(IVIVE) of the results and some aspects relating to different preclinical species used in 
NCE in vitro metabolic stability evaluation.
Thus far, several good reviews in the field have been published (2, 10–16). The above 
mentioned papers, however, were mainly focused on single issues such as in vitro metabolic 
stability testing development, comparison of methods for the assessment of drug metabolic 
stability, and prediction of in vivo metabolic parameters using data from in vitro assays.
METABOLIC STABILITY AND ITS SIGNIFICANCE
Metabolic stability refers to compound susceptibility to biotransformation. Both in 
vitro half-life (t1/2) and intrinsic clearance (CLint) are utilized to express metabolic stability. 
t1/2 is used to express the time for 50 % disappearance of the parent compound, whereas 
CLint describes the maximum activity of liver (microsomal proteins or hepatocytes) 
towards a compound not influenced by other physiological determinants such as hepatic 
blood flow and drug binding within the blood matrix (2, 17). Further, additional indices 
including the compound hepatic clearance (CLH), bioavailability, and in vivo half-life can 
be predicted with different models (2, 18–21).
As most therapeutic compounds are biotransformed in the liver tissue, especially CLH 
parameter is of great importance during drug development (16).
When NCE metabolic stability is evaluated with a liver microsomal model, microsomal 
intrinsic clearance (CLint,micr) is determined. CLint,micr (µL min–1 mg–1) is then scaled to in 
vivo intrinsic (hepatic) clearance (CLint) (mL min–1 kg–1) using suitable scaling factors 
[including microsomal protein content per gram of liver (MPPGL) and liver mass] obtained 
from the literature (Table I) (2, 19, 20, 22, 23).
NCE metabolic stability can be interpreted using different approaches, since 
compounds can be ranked in terms of their CLint and in vitro t1/2 values or based on parent 
structure loss during metabolic reactions. According to Di and Obach (31), the low limit of 
CLint,micr measurements is about 12 µL min–1 mg–1 protein. McNaney et al. (20) classified 
compounds with CLint above 45 mL min–1 kg–1 as high clearance compounds, NCE with 
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CLint values between 15 and 45 mL min–1 kg–1 as intermediate clearance compounds, and 
agents with CLint below 15 mL min–1 kg–1 as low clearance compounds.
High CLint and the corresponding low in vitro t1/2 values mean that the compound is 
rapidly metabolized, and its bioavailability in vivo will probably be low (2). Therefore, 
compounds can be classified on the basis of their t1/2 values; e.g., in case of human CYP3A4 
supersomes, compounds with t1/2 > 30 min were classified as long t1/2 compounds (e.g., 
carbamazepine and antipyrine); moderate t1/2 agents (e.g., ketoconazole) were characterized 
with t1/2 in the range between 10 and 30 min, and short t1/2 compounds (e.g., loperamide and 
buspirone) were those with t1/2 below 10 min (32). On the other hand, in case of the 
microsomal stability assay with mouse liver microsomes, the following t1/2 classification 
was suggested: compounds with t1/2 ≥ 60 min were defined as being stable in MLM and 
those with t1/2 < 30 min were categorized as unstable agents (33).
Moreover, the parent structure loss can be monitored during an appropriate incubation 
period (e.g., after 15 min) and three categories of substrate depletion can be distinguished: 
very fast (> 80 %), fast (50–80 %), moderate (20–50 %), slow (5–19 %), and very slow (< 5 %) (34).
Successful drug molecules should achieve and maintain sufficient concentrations at 
their sites of action and should be removed slowly from the body to ensure appropriate 
exposure to allow its effectiveness. In this context, the biggest challenges for the 
pharmaceutical industry during the drug discovery and development process are high 
clearance values, high metabolic liability and the formation of active or toxic metabolites (35). 
It is noteworthy that compounds demonstrating high clearance values are usually 
immediately removed from the body, which leads to short duration of their therapeutic 
effect. On the other hand, lower clearance compounds are characterized by reduced doses, 
Table I. Metabolic stability in liver microsomes, in vitro half-life and intrinsic clearance determination
Symbol Description How to calculate/establish Unit References
t1/2 In vitro 
half-life
Established from the slope of linear 
regression of the percentage parent 
compound remaining against time
min 2, 24, 25
CLint,micr Microsomal 
intrinsic 
clearance
Based on the equation: 
Clint,micr = ln 2/t1/2 × [volume of incubation 
medium (µl)/microsomal protein in 
incubation (mg)]
µL min–1 mg–1 2, 24–26
CLint In vivo 
intrinsic 
(hepatic) 
clearance
Estimated from liver microsomal data using 
the equation and suitable scaling factors: 
CLint = CLint,micr × (mg microsome g–1 liver)  
× [liver mass (g)/body mass (kg)]
Scaling factors: 
45 mg of microsomal protein per gram of 
liver tissue (humans, mice, rats, dogs, 
monkeys/value is applied to all species) 
87 g, 40 g, 30 g, 32 g, and 26 g of liver tissue 
per kilogram of body weight is used for mice, 
rats, dogs, monkeys, and humans, resp.
mL min–1 kg–1 26–30
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enhanced exposure and prolonged half-life and are hence suitable for once-daily dosing 
(31, 36–39). Table II provides some examples of drugs in use characterized by low, 
intermediate or high clearance values. 
Today, in the drug discovery process great emphasis is put upon the identification of 
NCEs with most favourable metabolic profiles (41–43). Therefore, in-depth analysis of the 
chemical structure of drug candidates and identification of molecule fragments mostly 
responsible for its biotransformation are conducted. Modification of these “soft spots” 
provides the opportunity to improve the metabolic characteristics of new chemical 
compounds (12, 44).
Favourable metabolic stability profiles of NCEs are characterized by prolonged half-
life and enhanced bioavailability. Moreover, reduction in metabolic turnover rates from 
different species is beneficial (35).
Assessment of metabolic stability. – It is vital to conduct metabolic stability studies of 
NCEs during the early phases of the drug discovery process, since despite showing 
promising in vitro activity, some molecules failed during in vivo evaluation due to poor 
pharmacological and toxicological results (31).
In general, drug metabolism studies are based on in vitro cellular/sub-cellular and in 
vivo animal models (14, 36, 37, 45–48). Undoubtedly, studies conducted in vivo with animal 
models are the most valuable source of data regarding NCE absorption, distribution, 
metabolism and excretion (ADME). Most importantly, results obtained with in vivo assays 
provide a complex pharmacokinetic profile of potential drug candidates. Notwithstanding, 
tests conducted in living systems are time-consuming, expensive and are not suitable for 
huge amounts of compounds. Therefore, the most recommended strategy involves 
preliminary in vitro assays that ensure selection of the optimal in vivo model to be employed 
in further drug development stages (35, 49–51).
Table II. Some examples of low, intermediate and high clearance drugs 
(assay in human liver microsomes, HLM)a
Intrinsic clearance 
(mL min–1 kg–1)
Low Intermediate High
Quinidine – 3.4 Chlorpromazine – 25.0 Verapamil – 122.0
Clozapine – 4.6 Imipramine – 19.0 Propafenone – 166.0
Dexamethasone – 3.0 Ketamine – 27.0 Midazolam – 160.0
Prednisone – 2.7 Triazolam – 19.0 Diclofenac – 189.0
Diazepam – 2.3
Zolpidem – 2.8
Tenoxicam – 1.7
a Ref. 40.
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In vitro metabolic models represent a valuable alternative to animal testing, especially 
when large libraries of NCEs need to be evaluated and when small quantities of investigated 
compounds are available. Preliminary in vitro data provide the opportunity of targeted 
synthesis of compounds with favourable metabolic profiles, thus leading to significant cost 
and time reduction (2, 7, 34, 48).
Metabolic stability testing can be performed by in vitro incubation of a compound 
with suitable competent metabolic models (e.g., liver microsomes, hepatocytes, cDNA-
expressed CYP enzymes). Next, chromatographic analysis (e.g., HPLC-MS/MS) of the 
resulting incubation mixtures is performed (52–54).
Among the routinely used metabolic stability in vitro systems are microsomes and 
hepatocytes. Microsomes are usually used to assess the CYP-mediated phase I metabolism. 
Some of the most important advantages of using microsomes are accessibility, various 
species models, procedure simplicity, limited amount of test agents used in the study and 
the fact that microsmes can be stored for a long period of time. On the other hand, 
hepatocytes, which contain intact cell membranes and physiological concentrations of 
enzymes, provide the most physiologically relevant model for predicting hepatic clearance 
(2, 15, 18, 37, 39, 48, 55–58). Some researchers use microsomes in conjunction with 
hepatocytes to obtain more comprehensive results (7, 55, 59–61).
Metabolic stability in liver microsomes. – In microsomal stability assays, microsomes 
coming from different species are used (e.g., human liver microsomes, HLM; mouse liver 
microsomes, MLM; rat liver microsomes, RLM; monkey liver microsomes, MnLM, or dog 
liver microsomes, DLM) (62). When human instead of animal based tests are applied, 
human clinical outcomes can be assessed (16). Interestingly, stability assays with MLM are 
not considered an ideal model for further in vivo experiments with mice. On the other 
hand, MLM is a good preliminary in vitro tool that can correlate well with the results 
obtained in metabolic assays with HLM (63, 64).
In general, during in vitro metabolic stability assays, compounds are incubated with 
liver microsomes from different species. Chromatographic techniques are then used for 
metabolite identification (65). 
In a typical microsomal stability assay, the incubation mixture consists of a test 
compound (dissolved in, e.g., acetonitrile, DMSO or methanol), liver microsomes, NADPH-
regenerating system, and potassium phosphate buffer. In order to prevent too much non-
specific binding, protein concentrations usually do not exceed 2 mg mL–1. In the first step, 
the mixture containing microsomes, test compound and buffer is pre-incubated at 37 °C 
for 15 min before addition of the NADPH-regenerating system. Then, the resulting mixture 
is incubated at 37 °C for several time intervals (e.g., 15, 30 and 60 min). Incubation is usually 
not longer than 60 min to provide optimal conditions for enzymatic activity. Subsequently, 
an internal standard is added and the samples are quenched by the addition of chemicals 
such as perchloric acid, ice-cold methanol or cold acetonitrile. Next, the samples are 
centrifuged and supernatants are analyzed using chromatography methods to determine 
the metabolic profile of the test compound. For control samples, the NADPH-regenerating 
system is replaced by phosphate buffer (2, 31, 66–76).
Metabolic stability in hepatocytes. – In the metabolic assay, hepatocytes coming from 
different species can be used (e.g., human, mouse, rat and dog). Hepatocyte cultures 
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represent a complex metabolic system, equipped with natural orientation for linked 
enzymes, intact cell membranes and all the necessary physiological co-factors (14, 15, 37, 
56–59). On the other hand, one of the main concerns about using freshly isolated human 
hepatocytes for predicting metabolic stability is their longer-term availability and their 
de-differentiation in culture (16, 31, 39, 48, 77, 78). To solve this problem, cryopreserved 
hepatocytes can be used (79). Moreover, some new strategies were developed, including 
highly specialized systems such as HepatoPac or LiverChip. HepatoPac is a micropatterned 
hepatocyte-fibroblast co-culture system that can be used for continuous incubation of up 
to 7 days, whereas LiverChip applies to a microfluidically perfused 3D hepatocyte culture 
system and was found useful in making low clearance measurements (2, 31, 39, 48, 55, 80).
During a standard procedure, hepatocyte suspensions containing 106 cells mL–1 are 
prepared. After preincubation of the cell suspension (10 min, 37 °C, 5 % CO2), the 
investigated compound solution (e.g., in DMSO) is added to the cells. The resulting mixture 
is then incubated again. Samples are taken at different time points (e.g., 15, 30, 60 and 
90 min), and reactions are stopped with ice-cold acetonitrile or methanol. Hepatocyte-free 
control incubations are prepared alongside by spiking a test compound sample into culture 
media and aliquots are collected at 0 and 90 min. Supernatants are then analyzed using 
chromatography methods for parent drugs and their metabolites (55, 63–65, 81–83).
Metabolic stability in recombinant expressed enzymes. – Recombinant expressed enzymes 
provided usually by the baculovirus or the human lymphoblastoid system are the source 
of specific P450 isoenzymes. Among the main advantages of using the recombinant 
expressed enzyme model in NCE stability testing are the simplicity of the method and the 
possibility of using single enzymes for the study. On the other hand, the absence of the 
remaining phase I and phase II enzymes can be considered as a drawback of this system 
(2, 15).
In a standard assay procedure, the incubation mixture is composed of a test compound 
solution, recombinant P450 isoenzymes, potassium phosphate buffer and MgCl2. Firstly, 
the mixture is pre-incubated for 15 min at 37 oC. Then, NADPH is added to start the 
metabolic reaction and incubation is continued for different time points (up to 60 min). The 
reaction is terminated by the addition of an acetonitrile containing internal standard. After 
centrifugation, aliquots of the samples are analyzed using LC-MS/MS to remove 
precipitated proteins (77, 82, 84, 85).
IN VITRO-IN VIVO EXTRAPOLATION
Prediction of human pharmacokinetic indices using in vitro data still remains a big 
challenge in the drug discovery and development process (86, 87). Rergarding the drug 
metabolic stability testing, IVIVE is an important tool for estimating the hepatic metabolic 
clearance of NCEs.
When analyzing metabolic stability data coming from different in vitro models, several 
important issues should be taken into consideration. First of all, both the rate of metabolism 
and metabolic enzymes activities observed in vitro should be close to in vivo conditions. 
Secondly, liver should be the major organ relating to NCE clearance and non-specific 
protein binding should be eliminated. Moreover, the compound concentration in the 
incubation mixture should be below the Michaelis-Menten constant (KM) (2, 14).
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Microsomal and hepatocyte stability assays are the key elements in high-throughput 
screening (HTS) of NCEs enabling the prediction of in vivo hepatic clearance. IVIVE 
procedure is based on the use of suitable scaling factors in order to transform the units of in 
vitro measured metabolic clearance to the rate of metabolism per gram of liver. Scaling 
factors depend on the in vitro system used. To obtain intrinsic clearance of the whole organ, 
the results are further multiplied by liver mass (Table I). There are appropriate scaling factors 
for data obtained with particular in vitro models, such as milligram of microsomal protein 
per gram of liver (MPPGL) for liver microsomes, number of hepatocytes per gram of liver 
(hepatocellularity, HPGL) for hepatocytes, and milligram of homogenate protein per gram 
of liver (Hom PGGL) when liver homogenates are employed (19, 45, 81, 88–91).
Many researchers have noticed that factors can influence prediction accuracy (92). In 
case of human MPPGL and HPGL values, inter-individual variability exists (e.g., in case of 
human MPPGL – 32 mg g–1 vs. the most commonly used 45 mg g–1, in case of HPGL – 99 × 
106 cells g–1 vs. the most commonly used 120 × 106 cells g–1) (19, 61, 68). In their study, Zhang 
et al. (61) proved that the mean value of MPPGL in 128 human livers was 39.46 mg g–1 and 
that up to 19-fold individual variations existed. Therefore, scaling factors should be matched 
to the population used.
Another problematic point relating to IVIVE are compounds that are extensively bound 
to plasma proteins (50, 69, 92). Obach (28) compared in vivo hepatic clearance predicted from 
in vitro models and CLH values measured in vivo and stated that in some cases, the clearance 
values predicted from the in vitro HLM model were substantially lower than those observed 
in vivo. It is noteworthy that such discrepancy was related to compounds with high protein 
binding.
According to some authors, in vitro metabolic stability assays conducted with liver 
microsomes represent a limited tool in predicting in vivo hepatic clearance in humans (93). 
On the other hand, the cryopreserved human hepatocytes model is regarded as a universal 
system suitable for such prediction (14, 53). It was observed that when metabolic liver 
microsomes assays were employed, a tendency to clearance over-prediction appeared. This 
happened particularly in the case of compounds with low passive membrane permeability 
(25). 
According to Chiba et al. (14), comparisons between the predicted and observed 
metabolic clearance in human using different datasets have indicated that the in vitro 
metabolic clearance obtained from both human liver microsomes and cryopreserved human 
hepatocytes systematically under-predicted in vivo metabolic clearance approximately 9 and 
3 to 6-fold, resp.
Some authors investigated the direct in vitro-in vivo relationship of NCEs biotransofor-
mation. Li et al. (69) evaluated the metabolism and pharmacokinetics of 4-(3,4,5-tri methoxy-
benzoyl)-2-phenylthiazole (SMART-H) that inhibited the proliferation of a variety of cancer 
cells in vitro and demonstrated that predicted clearance based on in vitro data correlated well 
with in vivo clearance in three animal models used in the experiment. In another study, 
Mukkavilli et al. (63), who examined a compound denoted as DNDI-VL-2098, a potential oral 
agent for visceral leishmaniasis, showed a close relationship between in vivo clearance in 
animal models and in vitro microsomal intrinsic clearance.
In vitro interspecies differences of NCE metabolic stability. – During in vitro metabolic 
stability testing, systems based on different preclinical species are employed (i.e., human, 
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mouse, rat, dog and monkey). As different model organisms are used in the experiments, 
interspecies variations in metabolic stability are typically observed (9, 30, 38, 94–98).
One of the most important advantages of using different in vitro animal models in NCE 
metabolic stability assessment is the direct interspecies comparison of metabolic turnover 
rates and metabolic pathways. This may aid the selection of an appropriate animal model 
for further in vivo studies and to identify suitable surrogate species to humans, ensuring 
both cost and time reduction in the future in vivo experiments (35).
Interestingly, it has been regarded natural that monkey metabolism is most similar to 
that of humans; cynomolgus monkeys have been widely used in pharmacokinetic or drug-
safety studies for that reason (99).
With reference to some drugs in use, Singh et al. (9) examined in vitro t1/2 and CLint,micr of 
imipramine in human, rat, mouse and dog microsomes and observed the highest t1/2 values 
Table III. In vitro half-life (t1/2) and intrinsic clearance (Clint) data on some NCEs obtained with liver 
microsomes from various preclinical species
Compound
Species
Re
fe
re
nc
e
Human Mouse Rat Monkey Dog
Mean Mean Mean Mean Mean
t 1
/2
(m
in
)
C
l in
t
(µ
L 
m
g–
1  m
in
–1
)
t 1
/2
 (m
in
)
C
l in
t
(µ
L 
m
g–
1  m
in
–1
)
t 1
/2
(m
in
)
C
l in
t
(µ
L 
m
g–
1  m
in
–1
)
t 1
/2
 (m
in
)
C
l in
t
(µ
L 
m
g–
1  m
in
–1
)
t 1
/2
 (m
in
)
C
l in
t
(µ
L 
m
g–
1  m
in
–1
)
SB639 59 – 3 – 6 – – – 60 – 94
I-387 24 – 37 – 42 – 15 – 29 – 95
SMART-H 17 – << 5 – 31 – – – 19 – 69
KBP-7018 – 90 – 40 – 70 – 440 – 120 30
SCY-078 ≥ 42 34 ≥ 125 ≤ 11 ≥ 125 ≤ 11 – – ≥ 29 ≤ 48 100
AG-024322 720 – – – 18 – 2220 – 60 – 101
Orteronel® > 60 4 > 60 3 > 60 8 > 60 3 > 60 4 98
E6201 36 – 84 – 89 – – – 70 – 96
FTY720-C2 – 18 – 23 – 80 – 20 – 6 97
FTY720-Mitoxy – 18 – 2 – 8 – 135 – 1 97
S002-333 – 27 – – – 133 – 137 – 60 102
S004-1032 – 25 – – – 147 – 70 – 50 102
S007-1558 – 36 – – – 562 – 318 – 70 102
AZ’0908 – 19 – – – 14 – – – 93 103
PF-02413873 30 29 – – < 2 > 500 – – 25 36 82
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(and thus low CLint,micr) in human and dog microsomes (65 and 47 min, resp.), whereas the 
lowest parameters were those in mouse and rat microsomes (11 and 5 min, resp.).
Table III gives the in vitro half-life and intrinsic clearance data of some NCEs obtained 
with liver microsomes from various preclinical species.
Pelkonen et al. (7), who compared metabolic stability of 55 validation compounds 
[European Centre for the Validation of Alternative Methods (ECVAM)/Interagency 
Coordinating Committee on the Validation of Alternative Methods (ICCVAM)] using human 
and rat liver homogenates and microsomes, observed that as regards metabolic stability, most 
compounds demonstrated similar behaviour in human and rat preparations. On the other 
hand, Kumar et al. (96) examined in vitro microsomal stability of a novel mitogen-activated 
protein kinase/extracellular signal-regulated kinase, kinase-1 (MEK1) inhibitor denoted as 
E6201, which showed faster metabolic clearance with HLM and the highest metabolic stability 
with RLM.
In another study Ahn et al. (95) conducted in vitro biotransformation of a novel antimitotic 
agent, I-387, in HLM, MLM, RLM, DLM and MnLM. They demonstrated that the test 
compound was most stable in RLM with the longest t1/2 and degraded rapidly in MnLM with 
the shortest t1/2. In case of HLM, t1/2 values were more similar to those of MLM and DLM than 
those of the other two species.
Similarly, the highest in vitro t1/2 was observed in RLM by Li et al. (69), who examined the 
metabolism of some 4-substituted methoxybenzoyl-aryl-thiazoles with the lead compound 
denoted as SMART-H. In HLM and DLM, in vitro half-lives were comparable, whereas the 
lowest t1/2 was observed in MLM. Comparable in vitro t1/2 between HLM and DLM were also 
reported by Venkatesh et al. (94) for compound SB639, a novel histone deacetylase inhibitor. 
Also, Wring et al. (100) evaluated the metabolic stability of SCY-078, the first-in-class orally 
active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis 
in microsomes coming from different species. The authors concluded that the investigated 
compound demonstrated low clearance with rodent microsomes and low to moderate 
clearance in dogs and humans. It was observed that SCY-078 was most stable in rodent 
microsomes and most widely metabolized in DLM. Interestingly, Zainuddin et al. (98), who 
investigated Orteronel®, a CYP17A1 enzyme inhibitor, demonstrated the highest CLint,micr in 
rat microsomes, whereas the lowest values of this parameter were noticed in mouse and 
monkey microsomes.
Zhong et al. (101) investigated in vitro the microsomal metabolism of compound AG-
024322, a novel cyklin-dependent kinase (CDK) inhibitor, employing HLM, RLM, DLM and 
MnLM. According to their results, the test compound depleted most extensively in RLM, 
followed by DLM. Moreover, comparable incubations in HLM and MnLM yielded significantly 
less extensive parent drug depletion. On the other hand, when Huang et al. (30) investigated 
the in vitro microsomal stability of KBP-7018, a new tyrosine kinase inhibitor candidate for 
treatment of idiopathic pulmonary fibrosis, the lowest CLint,micr was recorded in MLM and 
RLM, whereas the highest values were observed for MnLM.
Enoru et al. (97) assessed the preclinical metabolism of new blood-brain-barrier penetrant 
fingolimod analogues: FTY720-C2 and FTY720-Mitoxy. The in vitro intrinsic clearance of 
FTY720-C2 was low in dog, moderate in mouse, monkey and human, and high in rat, whereas 
in the case of the second analogue, FTY720-Mitoxy, the intrinsic clearance was found to be 
low in mouse, rat and dog, moderate in human and high in monkey.
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In another study, Saxena et al. (102) characterized the metabolism of S002-333 
[2-(4’-methoxy-benzenesulfonyl)-2,3,4,9-tetrahydro-1H-pyrido(3,4-b)indole-3-carboxylic acid 
amide] and its enantiomers, S004-1032 and S007-1558, using liver microsomes from different 
species. In case of compound S002-333, the highest CLint values were noted in MnLM and 
were comparable to the values for RLM. The lowest intrinsic clearance values were reported 
for HLM. In the case of enantiomers, the highest CLint was observed for RLM, whereas the 
lowest were those for rabbit liver microsomes.
Bylund and Bueters (103) evaluated compound AZ’0908, a novel microsomal 
prostaglandin E synthase-1 inhibitor intended for oral administration. The authors found 
that Clint values in liver microsomes were significantly higher in dog than in rat and human. 
It is noteworthy that Bungay et al. (82), who investigated in vitro stability of PF-02413873 
(4-[3-cyclopropyl-1-(methylsulfonylmethyl)-5-methyl-1H-pyrazol-4-yl]oxy-2,6-
dimethylbenzonitrile), a non-steroidal progesterone receptor antagonist, observed the 
highest Clint values in RLM, whereas in DLM and HLM clearance values were significantly 
lower than in rat.
In summary, the above data show clearly that compounds exhibit interspecies variability 
in their metabolic stability, since their in vitro half-lives and intrinsic clearance values usually 
vary greatly when different human or animal microsomes are used. It is therefore difficult to 
make compound metabolic stability cross-species predictions and each model should be 
tested to obtain reliable data, especially in the context of further in vivo experiments. These 
differences in drug metabolism result from many factors, such as differences in the primary 
sequence and levels of CYP isoforms between various species as well as differences in their 
hepatic metabolism (15, 104, 105).
CONCLUSIONS
During the drug discovery and development process, preclinical metabolic stability 
studies are essential to determine pharmacological and toxicological profiles of new chemical 
compounds. In the early phases of drug discovery, NCEs metabolic properties are determined 
using different in vitro systems. The obtained in vitro metabolism data are further used to 
predict the in vivo clearance of compounds. Moreover, preliminary in vitro experiments are 
useful in the selection of appropriate animal models for further in vivo studies and to identify 
suitable surrogate species to humans, ensuring both cost and time reduction in the future 
experiments. Despite the fact that in vitro-in vivo extrapolation procedures raise some 
questions, scientists are still working on improving this strategy to achieve more satisfactory 
predictions.
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